Ligand Pharmaceuticals stock has delivered a very strong 327.2% return over the past three years, while recent valuation checks point in different directions. A Discounted Cash Flow (DCF) estimate suggests the shares trade below intrinsic value, whereas market multiples indicate a richer valuation.

• The 327.2% gain over three years suggests that expectations have reset higher and leaves less room for simple mean reversion arguments to explain the current share price.
• Stronger royalty revenue and the recent expansion of the royalty portfolio can support longer term cash flow, while the use of zero coupon convertible debt may add future dilution risk that investors need to factor into what they are willing to pay today.
• Ligand Pharmaceuticals currently passes only 2 of 6 valuation checks, so the broader picture leans more towards expensive than clear bargain, even though the DCF view implies the stock trades at roughly a 32.4% discount to intrinsic value.

The key question is whether that combination of strong past returns and conflicting valuation signals still leaves enough potential upside in Ligand Pharmaceuticals to justify the current price.

Does Ligand Pharmaceuticals Look Undervalued on Cash Flow?

The Discounted Cash Flow (DCF) model values Ligand Pharmaceuticals based on the cash it is expected to generate for shareholders. The latest twelve month free cash flow is about $130.1 million, and the 2 Stage Free Cash Flow to Equity model assumes that these cash flows grow over time rather than shrink. On that basis, the model estimates an intrinsic value of about $427 per share.

This intrinsic value sits above the current share price, which implies the stock screens as roughly 32.4% undervalued on a cash flow basis. Because the recent $700 million zero coupon convertible debt financing can add future dilution, some investors may question how much of that DCF value ultimately flows to each share. Despite the reported growth in royalty revenue and the expansion of the royalty portfolio, the market still prices Ligand Pharmaceuticals below what this cash flow model suggests.

Based on the DCF numbers alone, Ligand Pharmaceuticals stock appears undervalued relative to the cash flows implied by this model.

Our Discounted Cash Flow (DCF) analysis suggests Ligand Pharmaceuticals is undervalued by 32.4%. Track this in your watchlist or portfolio, or discover 49 more high quality undervalued stocks.

Is Ligand Pharmaceuticals Getting Expensive on Earnings?

P/E is a useful yardstick for Ligand Pharmaceuticals because the company reports positive earnings and investors often focus on profitability for royalty driven businesses. The stock trades on a P/E of about 29.2x, which is higher than the Pharmaceuticals industry average of about 17.1x and above the peer group average of about 17.7x.

On the Fair P/E Ratio framework, which adjusts for factors such as growth profile, margins, size and risk, Ligand Pharmaceuticals screens on a fair multiple of about 22.3x. That is below the current 29.2x level, so the shares trade at a premium to what this tailored benchmark implies even after considering company specific characteristics.

On the P/E multiple, Ligand Pharmaceuticals stock appears overvalued compared with both sector norms and the modelled fair ratio.

The Ligand Pharmaceuticals Narrative: What Would Justify Today's Price?

Simply Wall St Narratives help connect the valuation puzzle around Ligand Pharmaceuticals' DCF and P/E signals with the specific assumptions that would need to hold on growth, margins and earnings for the stock to be worth much more or much less than it is today. Each Narrative links a fair value to a clear story about Ligand Pharmaceuticals' potential catalysts and risks so you can see over time which version of events appears to be taking shape.

The community is split on Ligand Pharmaceuticals, with one camp focused on compounding royalty cash flows and the other on concentrated risks and rich expectations.

Bull case: 26% undervalued

"A growing base of commercial drivers such as Filspari, Ohtuvayre, Qarziba and Merck partnered vaccines, together with 14 late stage XOMA programs and over 100 earlier stage assets, creates a diversified pool of potential future launches that can broaden royalty revenue and smooth earnings volatility..."

Bear case: 8% overvalued

"The pending acquisition of XOMA Royalty significantly increases exposure to development and regulatory risk across more than 120 additional assets..."

Do you think there's more to the story for Ligand Pharmaceuticals? Head over to our Community to see what others are saying!

The Bottom Line

Ligand Pharmaceuticals screens as undervalued on a Discounted Cash Flow (DCF) basis, yet looks overvalued on earnings multiples, and the broader valuation checks are weak. The split comes from cash flow models giving more credit to future royalty streams, while the higher P/E reflects rich expectations already in the price. After such a strong move, the key question is whether royalty growth and deal execution are solid enough to justify the premium multiple, rather than the stock slipping toward the lower intrinsic value implied by more cautious scenarios.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.